US EditionPublished • loading... • Updated
Johnson & Johnson highlights promising first-in-human Erda-iDRS (formerly TAR-210) results in intermediate-risk non-muscle-invasive bladder cancer
Summary by The Norfolk Daily News
4 Articles
4 Articles
Johnson & Johnson Highlights Promising First-in-human Erda-iDRS (formerly TAR-210) Results in Intermediate‑risk non–muscle-invasive Bladder Cancer - Life Sciences British Columbia
Johnson & Johnson announced results from a multicenter Phase 1 study evaluating investigational intravesical drug-releasing system.
Coverage Details
Total News Sources4
Leaning Left0Leaning Right0Center1Last UpdatedBias Distribution100% Center
Bias Distribution
- 100% of the sources are Center
100% Center
C 100%
Factuality
To view factuality data please Upgrade to Premium
